Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 29;10(1):94.
doi: 10.3390/jcm10010094.

Therapeutical Management and Drug Safety in Mitochondrial Diseases-Update 2020

Francesco Gruosso  1 , Vincenzo Montano  1 , Costanza Simoncini  1 , Gabriele Siciliano  1 , Michelangelo Mancuso  1
Affiliations
Review

Therapeutical Management and Drug Safety in Mitochondrial Diseases-Update 2020

Francesco Gruosso et al. J Clin Med. .

Abstract

Mitochondrial diseases (MDs) are a group of genetic disorders that may manifest with vast clinical heterogeneity in childhood or adulthood. These diseases are characterized by dysfunctional mitochondria and oxidative phosphorylation deficiency. Patients are usually treated with supportive and symptomatic therapies due to the absence of a specific disease-modifying therapy. Management of patients with MDs is based on different therapeutical strategies, particularly the early treatment of organ-specific complications and the avoidance of catabolic stressors or toxic medication. In this review, we discuss the therapeutic management of MDs, supported by a revision of the literature, and provide an overview of the drugs that should be either avoided or carefully used both for the specific treatment of MDs and for the management of comorbidities these subjects may manifest. We finally discuss the latest therapies approved for the management of MDs and some ongoing clinical trials.

Keywords: mitochondrial diseases; mitochondrial toxicity; therapies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Gorman G.S., Schaefer A.M., Ng Y., Gomez N., Blakely E.L., Alston C.L., Feeney C., Horvath R., Yu-Wai-Man P., Chinnery P.F., et al. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann. Neurol. 2015;77:753–759. doi: 10.1002/ana.24362. - DOI - PMC - PubMed
    1. Giles R.E., Blanc H., Cann H.M., Wallace D.C. Maternal inheritance of human mitochondrial DNA. Proc. Natl. Acad. Sci. USA. 1980;77:6715–6719. doi: 10.1073/pnas.77.11.6715. - DOI - PMC - PubMed
    1. Stewart J.B., Chinnery P.F. The dynamics of mitochondrial DNA heteroplasmy: Implications for human health and disease. Nat. Rev. Gene. 2015;16:530–542. doi: 10.1038/nrg3966. - DOI - PubMed
    1. Lake N.J., Compton A.G., Rahman S., Thorburn D.R. Leigh syndrome: One disorder, more than 75 monogenic causes. Ann. Neurol. 2016;79:190–203. doi: 10.1002/ana.24551. - DOI - PubMed
    1. DiMauro S., Schon E.A. Mitochondrial respiratory-chain diseases. N. Engl. J. Med. 2003;348:2656–2668. doi: 10.1056/NEJMra022567. - DOI - PubMed